Study to Access the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study
to evaluate the efficacy and safety of STI-1558 in adult subjects with mild/moderate
COVID-19. One thousand and two hundred adult subjects with mild/moderate COVID-19 (including
subjects with high risk factors for progression into severe cases) are planned to be enrolled
and randomized in a ratio of 1:1 into the test group or the placebo group (600 in the test
group and 600 in the placebo group).